Contrast media come under axe in Japan
This article was originally published in Clinica
Imaging contrast agents will suffer the biggest price cut in Japan's general reimbursement price revision this April with an average 9.6% reduction in tariff prices. The overall price cut for medical devices is expected to be around 5-6% (see Clinica No 896, pp 1-2).
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.